Payment overview · 2025
General Payments
$1,130.02
71 reported records · 12 companies
Healthcare provider profile · identity verified
Abdrhman Hamo, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · BECKLEY, WV · NPI 1295949907
Verified facts
What the public records show
CMS Open Payments records show Abdrhman Hamo, MD received $1,130.02 in general payments during 2025 across 71 reported records.
Kestra Medical Technology Services, Inc. accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 695 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $205.08 | 18.1% | 21 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $194.14 | 17.2% | 13 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $152.96 | 13.5% | 14 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $129.36 | 11.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $116.70 | 10.3% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $114.61 | 10.1% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $59.87 | 5.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.33 | 4.9% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.65 | 4.2% | 2 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $19.39 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.51 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.42 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,130.02 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $205.08 | 21 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $194.14 | 13 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $152.96 | 14 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $92.07 | 4 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $71.93 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $38.76 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.03 | 2 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $21.11 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| ORSIRO MISSION Normalized: orsiro mission |
Device | Teleflex LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 128 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
695 | 192 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 46 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 2193 | 707 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1752 | 644 |
| Clopidogrel | Clopidogrel Bisulfate | 1355 | 497 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 858 | 278 |
| Nitroglycerin | Nitroglycerin | 799 | 458 |
| Lisinopril | Lisinopril | 698 | 247 |
| Brilinta | Ticagrelor | 695 | 192 |
| Propranolol Hcl | Propranolol Hcl | 621 | 195 |
| Entresto | Sacubitril/Valsartan | 595 | 186 |
| Furosemide | Furosemide | 563 | 216 |
| Eliquis | Apixaban | 503 | 153 |
| Losartan Potassium | Losartan Potassium | 418 | 143 |
| Prasugrel Hcl | Prasugrel Hcl | 360 | 106 |
| Ranolazine Er | Ranolazine | 351 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 132 |
| Valsartan | Valsartan | 335 | 122 |
| Potassium Chloride | Potassium Chloride | 323 | 123 |
| Carvedilol | Carvedilol | 277 | 95 |
| Spironolactone | Spironolactone | 264 | 101 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 190 | 79 |
| Hydralazine Hcl | Hydralazine Hcl | 188 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 64 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 180 | 74 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 173 | 61 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 170 | 75 |
| Diltiazem Hcl | Diltiazem Hcl | 166 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 76 |
| Nifedipine Er | Nifedipine | 158 | 59 |
| Xarelto | Rivaroxaban | 138 | 42 |
| Farxiga | Dapagliflozin Propanediol | 128 | 46 |
| Candesartan Cilexetil | Candesartan Cilexetil | 124 | 45 |
| Chlorthalidone | Chlorthalidone | 103 | 32 |
| Jardiance | Empagliflozin | 99 | 40 |
| Amiodarone Hcl | Amiodarone Hcl | 95 | 38 |
| Cilostazol | Cilostazol | 90 | 32 |
| Simvastatin | Simvastatin | 81 | 26 |
| Atenolol | Atenolol | 80 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 34 |
| Clonidine Hcl | Clonidine Hcl | 60 | 24 |
| Propranolol Hcl Er | Propranolol Hcl | 58 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 24 |
| Sotalol | Sotalol Hcl | 52 | 16 |
| Ezetimibe | Ezetimibe | 44 | 20 |
| Digoxin | Digoxin | 43 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Theophylline Er | Theophylline Anhydrous | 41 | 11 |
| Verapamil Hcl | Verapamil Hcl | 41 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Famotidine | Famotidine | 28 | 11 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 28 | 11 |
| Midodrine Hcl | Midodrine Hcl | 25 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | 17 |
| Torsemide | Torsemide | 24 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 21 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Camzyos | Mavacamten | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,130.02 · 71 records | Kestra Medical Technology Services, Inc. | AVEIR, AVVIGO Guidance System, Assure WCD, FARXIGA, GALLANT, General - Balloon Catheters, Indigo System, Kerendia, LifeVest, ORSIRO MISSION, Penumbra System, Repatha, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VERQUVO, WAINUA, WATCHMAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error